Search
forLearn
5 / 801 resultslearn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn GT20029
research compound made to degrade androgen receptors in scalp
learn tamsulosin
learn retinoic acid
Research
5 / 1000+ results
research 50579 Novel Cosmetic Formulation Rapidly Reduces Hair Shedding
The new hair treatment significantly reduces hair shedding safely.
research Novel shampoo reduces hair shedding by contracting the arrector pili muscle via the trace amine‐associated receptor
New shampoo with tyramine hydrochloride reduces hair loss by making a small muscle in the hair follicle contract.
research A Novel Cosmetic Formulation That Rapidly Reduces Hair Shedding in Females
The new hair product quickly reduces hair shedding in women.
research Ectopic olfactory receptors in human: New therapeutic possibilities
Olfactory receptors found outside the nose may offer new treatments for diseases like cancer and help in wound healing and hair growth.
research Thyroid receptor agonists for the treatment of androgenetic alopecia
Thyroid receptor agonists may treat male pattern baldness without harmful side effects.
Community Join
5 / 1000+ resultscommunity GT20029. Kintor Pharma’s Product
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
community Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Kintor Pharmaceutical Announces AR-PROTAC (GT20029) Approved for Acne and Androgenic Alopecia Clinical Trials in China
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.